Search

Sudha Visvanathan Phones & Addresses

  • Mount Kisco, NY
  • Hartsdale, NY
  • Danbury, CT
  • 726 Adams St, Hoboken, NJ 07030
  • Chesterbrook, PA
  • Los Angeles, CA
  • West Chester, PA
  • Nutley, NJ

Publications

Us Patents

Serum Markers Predicting Clinical Response To Anti-Tnf Alpha Antibodies In Patients With Psoriatic Arthritis

View page
US Patent:
20120178100, Jul 12, 2012
Filed:
Jul 12, 2010
Appl. No.:
13/386998
Inventors:
Carrie Wagner - Chesterbrook PA, US
Sudha Visvanathan - Hoboken NJ, US
Assignee:
CENTOCOR ORTHO BIOTECH INC. - Horsham PA
International Classification:
G01N 33/566
G01N 33/573
G06N 3/08
C12M 1/40
US Classification:
435 74, 435 792, 4352872, 706 20
Abstract:
The invention provides tools for management of patients diagnosed with psoriatic arthritis, specifically, prior to the initiation of therapy with an anti-TNFα agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment the baseline levels of VEGF, prostatic acid phosphatase, and adiponectin are used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as MDC, lipoprotein a, and beta2-microglobulin.

Serum Markers Predicting Clinical Response To Anti-Tnfa Antibodies In Patients With Ankylosing Spondylitis

View page
US Patent:
20110251099, Oct 13, 2011
Filed:
Dec 9, 2009
Appl. No.:
13/140441
Inventors:
Sudha Visvanathan - Hoboken NJ, US
Carrie Wagner - Chesterbrook PA, US
International Classification:
C40B 30/04
G06F 19/10
C40B 60/08
G01N 30/00
C12Q 1/42
C12M 1/34
US Classification:
506 9, 435 21, 4352872, 506 37, 422 69, 702 19
Abstract:
The invention provides tools for management of patients diagnosed with ankylosing spondylitis and prior to the initiation of therapy with an anti-TNFalpha agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary end-points using serum marker concentrations. In one embodiment the baseline level of leptin or osteocalcin is used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as complement component 3.

Biomarkers Associated With Anti-Il-36R Antibody Treatment In Generalized Pustular Psoriasis

View page
US Patent:
20220290239, Sep 15, 2022
Filed:
Mar 10, 2022
Appl. No.:
17/691486
Inventors:
- Ingelheim am Rhein, DE
Ahmed Karim FARAG - Biberach, DE
Sudha VISVANATHAN - Hartsdale NY, US
International Classification:
C12Q 1/6883
G01N 33/564
C07K 16/28
Abstract:
This invention generally relates to biomarkers associated with anti-IL-36R antibody treatment in generalized pustular psoriasis (GPP). The invention also relates to methods of using the biomarkers disclosed.

Anti-Il-36R Antibodies For The Treatment Of A Fibrotic Condition

View page
US Patent:
20230049147, Feb 16, 2023
Filed:
Aug 12, 2022
Appl. No.:
17/819327
Inventors:
- Ingelheim am Rhein, DE
Marc Kaestle - Schemmerhofen, DE
Janine Lamar - Ingelheim, DE
David Lamb - Mittelbiberach, DE
Meera Ramanujam - Danbury CT, US
Sudha Visvanathan - Hartsdale NY, US
International Classification:
C07K 16/28
A61K 45/06
A61P 1/00
A61P 11/00
A61K 39/395
Abstract:
The present invention provides methods for treating, preventing or ameliorating a fibrotic condition. The methods of the present invention include administering to a patient suffering from a fibrotic condition a therapeutically effective amount an anti-interleukin-36 receptor (anti-IL-36R) antibody.

Methods Of Treating Inflammatory Diseases

View page
US Patent:
20200308271, Oct 1, 2020
Filed:
Dec 21, 2019
Appl. No.:
16/724225
Inventors:
- Ingelheim am Rhein, DE
Mary Ruth Flack - Ridgefield CT, US
Annette Bettina Galler - Armsheim, DE
Bojan Lalovic - Cedar Knolls NJ, US
Kaori Maino - Tokyo, JP
Steven John Padula - Southbury CT, US
Paul Scholl - Redding CT, US
Koji Sha - Tokyo, JP
Sudha Visvanathan - Hartsdale NY, US
Assignee:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH - Ingelheim am Rhein
International Classification:
C07K 16/24
A61K 39/395
A61P 17/06
C12Q 1/6883
Abstract:
This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic arthritis, utilizing anti-IL-23A antibodies.

Methods Of Treating Diseases

View page
US Patent:
20200299378, Sep 24, 2020
Filed:
Dec 13, 2019
Appl. No.:
16/714001
Inventors:
- Ingelheim am Rhein, DE
Wulf Otto BOECHER - Mainz/Rhein, DE
Annette Bettina GALLER - Armsheim, DE
Bojan LALOVIC - Cedar Knolls NJ, US
Sudha VISVANATHAN - Hartsdale NY, US
Assignee:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH - Ingelheim am Rhein
International Classification:
C07K 16/24
Abstract:
This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.

Methods Of Treating Diseases

View page
US Patent:
20190359701, Nov 28, 2019
Filed:
Mar 8, 2019
Appl. No.:
16/297563
Inventors:
- Ingelheim am Rhein, DE
Alix BERTON - Mölndal, DE
Michael Chadham NIVENS - Mittelbiberach-Reute, DE
Karsten QUAST - Schemmerberg, DE
Marco SCHLEPUETZ - Ulm-Soeflingen, DE
Sudha VISVANATHAN - Hartsdale NY, US
Assignee:
Boehringer Ingelheim International GmbH - Ingelheim am Rhein
International Classification:
C07K 16/24
A61K 39/395
C07K 16/46
Abstract:
This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.

Methods Of Treating Diseases

View page
US Patent:
20180334501, Nov 22, 2018
Filed:
Jun 27, 2018
Appl. No.:
16/019670
Inventors:
- Ingelheim am Rhein, DE
Alix Berton - Molndal, DE
Michael Chadham Nivens - Mittelbiberach-Reute, DE
Karsten Quast - Schemmerberg, DE
Marco Schlepuetz - Ulm-Soeflingen, DE
Sudha Visvanathan - Hartsdale NY, US
Assignee:
Boehringer Ingelheim International GmbH - Ingelheim am Rhein
International Classification:
C07K 16/24
C07K 16/46
A61K 39/395
A61K 39/00
Abstract:
This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
Sudha Visvanathan from Mount Kisco, NY, age ~55 Get Report